Supplemental Table 2 Competing hazard risks for renal and non-renal outcomes stratified by chronic kidney disease
stage
CKD
Hb level
ESKD
Crude
G1–2
G3
G4
G5
95% CI
HR
Death and CVEs
95% CI
Crude
95% CI
HR
95% CI
<10
−
−
1.89
0.43–8.39
−
≥12
−
−
0.50
0.23–1.10
−
<10
1.04
0.12–9.05
1.38
0.01–141.0
3.70
1.76–7.79
4.49
2.06–9.80
≥12
0.06
0.01–0.49
0.01
0.00–0.20
0.61
0.34–1.08
0.78
0.42–1.44
<10
2.59
1.42–4.72
3.08
1.40–6.79
1.06
0.52–2.19
0.45
0.18–1.11
≥12
0.74
0.37–1.50
0.52
0.24–1.10
0.33
0.14–0.82
0.64
0.23–1.76
<10
1.59
1.14–2.23
1.43
1.01–2.05
0.71
0.31–1.64
0.74
0.28–1.91
≥12
1.06
0.58–1.94
1.05
0.56–1.99
−
−
Crude and adjusted competing risks for end-stage kidney disease before non-renal outcomes (combined cardiovascular
events and all-cause mortality) and for non-renal outcomes before ESKD were calculated based on CKD stage
stratifications. Hb levels of 10–12 g/dL were used as reference. Bold font indicates statistical significance (P < 0.05).
Covariates in multivariable-adjusted models included age, sex, diabetes, history of cardiovascular disease, systolic
blood pressure, smoking, proteinuria, and use of ESAs, that were significantly associated with primary endpoints (all
factors, except for age, significantly predicted the composite endpoint).
Abbreviations: 95% CI, 95% confidence interval; CKD, chronic kidney disease; CVEs, cardiovascular events; ESKD,
end-state kidney disease; Hb, hemoglobin, HR, hazard ratio
The risk could not be calculated for ESKD in G1–2 because it did not occur in patients with Hb levels 10–12 and ≥12
g/dL. No incidence for non-renal outcome was observed before ESKD in G5 with Hb levels ≥12 g/dL.